Sarepta Therapeutics
Trade Sarepta Therapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
SRPT Key Statistics
Stock Snapshot
Sarepta Therapeutics(SRPT) stock is priced at $21.68, giving the company a market capitalization of 2.27B. It carries a P/E multiple of -7.42.
On 2026-01-14, Sarepta Therapeutics(SRPT) stock traded between a low of $20.95 and a high of $22.03. Shares are currently priced at $21.68, which is +3.5% above the low and -1.6% below the high.
Sarepta Therapeutics(SRPT) shares are trading with a volume of 1.29M, against a daily average of 3.07M.
In the last year, Sarepta Therapeutics(SRPT) shares hit a 52-week high of $123.51 and a 52-week low of $10.42.
In the last year, Sarepta Therapeutics(SRPT) shares hit a 52-week high of $123.51 and a 52-week low of $10.42.
SRPT News
H.C. Wainwright reiterates a Sell rating on Sarepta (SRPT) with a $5 price target saying the company’s preliminary Q4 Elevidys net product revenue of $110.4M im...
Needham analyst Gil Blum has maintained their bearish stance on SRPT stock, giving a Sell rating today. Claim 70% Off TipRanks Premium Unlock hedge fund-level d...
William Blair analyst Sami Corwin has reiterated their neutral stance on SRPT stock, giving a Hold rating today. Claim 70% Off TipRanks Premium Unlock hedge fun...
Analyst ratings
54%
of 26 ratingsMore SRPT News
12:01 EST Sarepta (SRPT) falls 10% to $21.37 after reporting preliminary Q4 revenue Published first on TheFly – the ultimate source for real-time, market-movin...
Sarepta (SRPT) Therapeutics reports preliminary fourth quarter and full-year 2025 net product revenues and cash, cash equivalents, restricted cash and investmen...
Sarepta Therapeutics has submitted a clinical trial application to New Zealand’s Medsafe for INSIGHTT, a first-in-human study of SRP-1005, its investigational s...
